Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Drug Majors Settle Generic Lawsuits

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Two of India's largest pharmaceutical companies - Ranbaxy Laboratories and Dr. Reddy's Laboratories - have settled litigation disputes with two major global drug firms
Advertisement

Related Content

Dr Reddy’s Launches Generic Versions Of GSK’s Imitrex; Ranbaxy May Have To Wait
Dr Reddy’s Launches Generic Versions Of GSK’s Imitrex; Ranbaxy May Have To Wait
Ranbaxy Sees Light At The End Of DoJ Investigation Tunnel - CEO Interview
Ranbaxy Sees Light At The End Of DoJ Investigation Tunnel - CEO Interview
PharmAsia News Notable Notes: GSK India Aims For Nine Product Launches In Two Years
PharmAsia News Notable Notes: GSK India Aims For Nine Product Launches In Two Years
Dr Reddy’s Earnings Plunge On German Unit Charge, Increased Generic Competition
Dr Reddy’s Earnings Plunge On German Unit Charge, Increased Generic Competition
Ranbaxy Delays Spin Off Of R&D Unit Until Later This Year
Ranbaxy Delays Spin Off Of R&D Unit Until Later This Year
Advertisement
UsernamePublicRestriction

Register

SC066711

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel